Navigation Links
Flagship Biosciences Launches New Clinical Diagnostics Service
Date:7/1/2020

Flagship Biosciences, providers of expert tissue data insights, today announced that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight. TissueInsight provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment (TME).

“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” said Trevor Johnson, Flagship CEO. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”

Flagship’s exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab delivers the highly accurate tissue scoring needed for precision medicine. Combined with its award-winning technology and sign-off from its experienced pathologists for every client, TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring. Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages.

“I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson. “Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immuno-oncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.”

About Flagship Biosciences

Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation for every client, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. flagshipbio.com

For more information please contact Pamela Curran of Stratos Global Marketing, at pam@stratosglobalmarketing.com or +1 (303) 818 9316.

Read the full story at https://www.prweb.com/releases/flagship_biosciences_launches_new_clinical_diagnostics_service/prweb17223687.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Predicine and Flagship Biosciences Partner to Support Global Biomarker Development
2. Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
3. Orthogonal Congratulates Nanowear on the FDA Clearance of their Flagship Product, SimplECG™.
4. Dr. Nancy Gillett Joins Flagship Biosciences' Board of Directors
5. Flagship Biosciences Expands Operations to Meet Tremendous Industry Growth Demands
6. Flagship Biosciences and Beaufort, LLC Partner to Provide Clinical Trial Services for the Pharmaceutical Industry
7. Flagship Ventures Brian Fiske Named To Forbes 30 Under 30 List
8. Flagship Creates Clinical Trials and Regulatory Affairs Group
9. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. Deep Knowledge Ventures Flagship Investment Insilico Medicine Finalist at GPU Tech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
(Date:7/22/2020)... TORONTO (PRWEB) , ... July 22, 2020 , ... Join ... and John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... is the regulating body in China for drugs and medical devices. Specifically, for medical ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... ... solutions to aid in the early detection and prevention of high-burden diseases, and ... enable US-based hospitals and healthcare organizations to utilize existing data in order to ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, ... magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ranking of ... as well, and for this year’s list, reported three-year revenue growth of 71 percent. ...
(Date:8/21/2020)... Rochelle, Virginia (PRWEB) , ... August 20, 2020 ... ... announced today that Hassan Movahhed , a Clinical Operations executive with expertise ... CRO management, has joined the firm as an Expert Consultant. Throughout his career, ...
(Date:8/5/2020)... ... 2020 , ... Regenative Labs has received approval from the Centers for Medicare ... the first Wharton’s jelly allografts to be assigned a Q code and be approved ... first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS ...
Breaking Biology News(10 mins):